SARS-CoV-2 Spike Binding Polypeptides for Viral Entry Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for effective compositions and methods to treat, prevent, and diagnose SARS-CoV-2 infections, particularly to inhibit the interaction between the SARS-CoV-2 spike protein and the ACE2 molecule, which is crucial for the virus's entry into cells.
Innovation Solution
Development of polypeptides, such as antibodies and antibody fragments, that specifically bind to the SARS-CoV-2 spike protein, including those with specific CDR sequences, which can inhibit the virus's entry into cells and be used in therapeutic, preventive, and diagnostic methods.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If polypeptides are designed to specifically bind SARS-CoV-2 spike protein, then viral entry inhibition is improved, but manufacturing complexity increases
Solution Approach 1:
The patent segments the antibody structure by defining specific CDR sequences from different sources (human, mouse, rabbit) that can be combined in modular fashion. This allows systematic production of multiple polypeptide variants with different binding specificities while using standardized framework regions, thereby improving manufacturability while maintaining viral entry inhibition capability.
Solution Approach 2:
The patent systematically varies CDR sequence parameters (amino acid composition, length, specificity) to optimize binding affinity to SARS-CoV-2 spike protein. By changing these molecular parameters while maintaining overall antibody structure, the patent achieves improved viral entry inhibition without requiring complete redesign of the production system.
2Measurement precision
If multiple CDR sequences are combined to enhance binding affinity, then detection precision is improved, but device complexity increases
Solution Approach 1:
The patent merges CDR sequences from multiple antibody sources (human, mouse, rabbit) into single polypeptide constructs. This combining of complementary CDR regions from different antibodies enhances binding affinity and detection precision for SARS-CoV-2 spike protein while maintaining a manageable single-chain polypeptide structure.
Solution Approach 2:
The patent creates polypeptides with universal applicability by combining CDR sequences that can recognize conserved regions of SARS-CoV-2 spike protein. These multi-functional polypeptides can serve both diagnostic detection and therapeutic inhibition purposes, reducing the need for separate specialized reagents.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These polypeptides effectively bind to the SARS-CoV-2 spike protein, inhibiting viral entry and providing a basis for treatment, prevention, and diagnosis of SARS-CoV-2 infections, offering a potential solution for managing COVID-19.
Implementation Method 1
polypeptides capable of binding to a SARS-CoV-2 spike protein... specifically bind to a SARS-CoV-2 spike protein... binding to the receptor binding domain (RBD) of the SARS-CoV-2 spike protein
Data Source
AI summary
Aspects of the present disclosure relate to polypeptides that specifically bind to a SARS-CoV-2 spike protein, and to methods of use for treatment, prevention, and diagnosis of a SARS-CoV-2 infection. Certain aspects are directed to antibodies and fragments thereof, including Fabs, configured to bind to various epitopes within the receptor binding domain (RBD) of a SARS-CoV-2 spike protein. Compositions, kits, and methods for detection of SARS-CoV-2 are also disclosed.